<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04241731</url>
  </required_header>
  <id_info>
    <org_study_id>JS-GI1901</org_study_id>
    <nct_id>NCT04241731</nct_id>
  </id_info>
  <brief_title>A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer</brief_title>
  <official_title>A Multicenter Phase II Clinical Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Cancer Institute &amp; Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maintenance treatment can extend patient survival and improve patient quality of life.&#xD;
      Bevacizumab alone or capecitabine combined with bevacizumab as a maintenance treatment have&#xD;
      been widely used in clinical practice. In contrast, there are little datas of cetuximab as a&#xD;
      maintenance treatment. The purpose of this study is to evaluate efficacy and safety of&#xD;
      Raltitrexed plus Cetuximab as the maintenance treatment, and to provide a new choice for RAS&#xD;
      wild-type colorectal cancer patients after advanced first-line chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maintenance treatment can prevent the toxicity and give patients a relative buffer period to&#xD;
      alleviate the impact of follow-up treatment on the body without reducing efficacy.&#xD;
      Bevacizumab alone or capecitabine combined with bevacizumab as a maintenance treatment have&#xD;
      been widely used in clinical practice. There are little datas of cetuximab as a maintenance&#xD;
      treatment ,some studies show that Cetuximab is effective in maintenance treatment, and some&#xD;
      studies have reported adverse effects of Capecitabine combined with Cetuximab.So it is&#xD;
      worthwhile to explore more suitable maintenance treatment options. Raltitrexed, a TS enzyme&#xD;
      inhibitor, is an effective chemotherapy drug for colorectal cancer. We plan to evaluate&#xD;
      efficacy and safety of Raltitrexed plus Cetuximab in maintenance treatment. Maybe we can&#xD;
      provide a new choice for RAS wild-type colorectal cancer patients after advanced first-line&#xD;
      chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2019</start_date>
  <completion_date type="Anticipated">November 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time from the beginning of first-line treatment until the disease progresses.</measure>
    <time_frame>24 months</time_frame>
    <description>Progression Free Survival 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The time from the beginning of maintenance treatment until the disease progresses.</measure>
    <time_frame>24 months</time_frame>
    <description>Progression Free Survival 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events Based on NCI-CTC 4.0</measure>
    <time_frame>24 months</time_frame>
    <description>evaluate the safety of patient medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>24 months</time_frame>
    <description>Based on QLQ-C30 in EORTC, evaluate the quality of life of patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Raltitrexed Plus Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltitrexed Plus Cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltitrexed</intervention_name>
    <description>Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.</description>
    <arm_group_label>Raltitrexed Plus Cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.</description>
    <arm_group_label>Raltitrexed Plus Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-75 years old, no gender restriction;&#xD;
&#xD;
          -  RAS wild-type&#xD;
&#xD;
          -  Unresectable metastatic colorectal cancer confirmed by histopathology and / or&#xD;
             cytology;&#xD;
&#xD;
          -  Disease stable or improved while on first-line use of FOLFOX/FOLFIRI with cetuximab&#xD;
             for 4-6 months;&#xD;
&#xD;
          -  At least one measurable objective tumor lesion by spiral CT scan，the longest diameter&#xD;
             measured ≧ 10 mm，or by conventional CT scan，the diameter measured ≧ 20 mm.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) general status score is 0-2;&#xD;
&#xD;
          -  Life expectancy of at least 3 months;&#xD;
&#xD;
          -  Blood routine, liver and kidney function within the 7 days before screening meet the&#xD;
             following criteria: Absolute neutrophil count ≥ 1.5x10^9 / L; hemoglobin ≥ 9.0 g / dl;&#xD;
             platelet count ≥ 80 x10^9 / L; total bilirubin ≤ 1.5 times the upper limit of normal&#xD;
             (ULN); alanine aminotransferase and aspartate aminotransferase ≤ 2.5 x ULN (≤5 x ULN&#xD;
             in patients with liver metastases); ≤3 x ULN in patients with liver metastases (≤5 x&#xD;
             ULN in patients with liver metastases); serum creatinine ≤1.5 x ULN;&#xD;
&#xD;
          -  Agree to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BRAF mutant&#xD;
&#xD;
          -  Symptomatic brain or meningeal metastases (unless patients receive treatment&gt; 6&#xD;
             months, imaging results are negative within 4 weeks before joining the study, and&#xD;
             tumor-related clinical symptoms are stable before joining the study);&#xD;
&#xD;
          -  Previous malignant disease within five years, with the exception of the cured primary&#xD;
             cervical cancer or basal cell carcinoma of the skin;&#xD;
&#xD;
          -  Chronic intestinal disease, infectious intestinal disease, intestinal obstruction,&#xD;
             active clinical severe infection and other diseases;&#xD;
&#xD;
          -  With ascites&#xD;
&#xD;
          -  Substance abuse and medical, psychological or social conditions that may interfere&#xD;
             with the participation of patients in the study or influence the evaluation of the&#xD;
             results of the study;&#xD;
&#xD;
          -  Unsuitable for the study or other chemotherapy determined by investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liangjun Zhu</last_name>
    <role>Study Chair</role>
    <affiliation>Jiangsu Cancer Institute &amp; Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liangjun Zhu</last_name>
    <phone>+8613905199123</phone>
    <email>zhulj98@foxmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sheng Li</last_name>
    <phone>+8613770768636</phone>
    <email>lihsh198@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangsu Cancer Institute &amp; Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liangjun Zhu</last_name>
      <phone>+8613905199123</phone>
      <email>zhulj98@foxmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sheng Li</last_name>
      <phone>+8613770768636</phone>
      <email>lihsh198@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jiangsu Cancer Institute &amp; Hospital</investigator_affiliation>
    <investigator_full_name>Liangjun Zhu M.M.</investigator_full_name>
    <investigator_title>Ward Director of Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

